Victor Hugo Valença Bomfim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Victor Hugo Valença Bomfim has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Edna Lúcia Souza
Universidade Federal da Bahia
1 shared publication - Elenara da Fonseca Andrade Procianoy
Hospital de Clínicas de Porto Alegre, Porto Alegre Rio Grande do Sul Brazil
1 shared publication - Gabriel Souza Medrado Nunes
Federal University of Bahia, Salvador, Brazil
1 shared publication - Laís Ribeiro Mota
Universidade Federal da Bahia, Brazil
1 shared publication - Luciana de Freitas Velloso Monte
Hospital da Criança de Brasília José Alencar Universidade Católica de Brasília Brasília Federal District Brazil
1 shared publication - Luiz Vicente Ribeiro Ferreira da Silva Filho
Universidade de São Paulo
1 shared publication
Latest Publications
- 10 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3) , e71557
CFTR Modulators in Brazil: Not for Everyone—A Comparison of Ineligibility Across Different Regions
Objectives: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. Methods: This cross‐sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the CFTR gene and/or elevated sweat chloride levels were included. Variables studied were treatment center, age at diagnosis, current age, sex, race/ethnicity, genotype, and ineligibility for ETI and IVA. The chi‐square test compared the distribution of race/ethnicity across centers and associations between ineligibility, treatment center, and the presence of the 3120 + 1 G > A variant. Binary logistic regression was applied to assess the strength of association between the main variables. Results: Six hundred forty‐nine individuals were included, with a median age at diagnosis and current age of 0.25 and 11.6 years, respectively. One hundred thirty‐eight participants (21.26%) were ineligible for ETI or IVA. Racial/ethnic distribution varied across centers, in the total sample, and among ineligible individuals. Non‐White individuals were 20% more likely to be ineligible than White individuals. The ineligibility for ETI did not vary significantly among the centers. Conclusions: The ineligibility for ETI was high across all analyzed regions, but was not different among the centers. In Brazil, characterized by widespread admixture, the public health policies must consider the genotypic heterogeneity and wide variation in ancestry of the Brazilian population.
- 10 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (3) , e71557
CFTR Modulators in Brazil: Not for Everyone—A Comparison of Ineligibility Across Different Regions
Objectives: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. Methods: This cross‐sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the CFTR gene and/or elevated sweat chloride levels were included. Variables studied were treatment center, age at diagnosis, current age, sex, race/ethnicity, genotype, and ineligibility for ETI and IVA. The chi‐square test compared the distribution of race/ethnicity across centers and associations between ineligibility, treatment center, and the presence of the 3120 + 1 G > A variant. Binary logistic regression was applied to assess the strength of association between the main variables. Results: Six hundred forty‐nine individuals were included, with a median age at diagnosis and current age of 0.25 and 11.6 years, respectively. One hundred thirty‐eight participants (21.26%) were ineligible for ETI or IVA. Racial/ethnic distribution varied across centers, in the total sample, and among ineligible individuals. Non‐White individuals were 20% more likely to be ineligible than White individuals. The ineligibility for ETI did not vary significantly among the centers. Conclusions: The ineligibility for ETI was high across all analyzed regions, but was not different among the centers. In Brazil, characterized by widespread admixture, the public health policies must consider the genotypic heterogeneity and wide variation in ancestry of the Brazilian population.